文献速递垂体与肾上腺疾病

成人生长激素缺乏症患者生长激素替代治疗长期安全性与耐受性的性别差异

Sex Differences in Long-Term Safety and Tolerability of GH Replacement Therapy in GH Deficient Adults.
PubMed 文献 · J Clin Endocrinol Metab · 2023-01-01

这项基于荷兰国家成人GH治疗登记处的回顾性队列研究纳入1335例男性和1251例女性GHD成人,发现女性IGF-1 SDS持续低于正常更常见(P<0.001)、不良事件更多(P<0.001)且更常需减量或暂停(P=0.001),男性恶性肿瘤风险更高(P=0.012),但两性停药率及2型糖尿病、良性肿瘤、肿瘤复发风险无差异。

要点

  • 女性GHD患者IGF-1 SDS持续低于正常更常见(P<0.001),男性高于正常更常见(P<0.001)。
  • 女性不良事件更多(P<0.001),尤其液体潴留症状,更常需减量或暂停(P=0.001)。
  • 男性恶性肿瘤风险更高(P=0.012),两性停药及2型糖尿病、良性肿瘤、肿瘤复发风险无差异。

核心结论

  • 荷兰国家成人GH治疗登记处数据提示GHD女性可能治疗欠优化,表现为IGF-1状态较低和GHRT耐受性较低,导致更频繁调整方案但不停药。
  • 长期安全性方面,GHD男性发生恶性肿瘤的风险更高。

研究设计与样本

  • 回顾性队列研究,在荷兰国家成人GH治疗登记处(全国性门诊诊所)开展。
  • 纳入接受GHRT的荷兰成人GHD男性1335例和女性1251例。
  • 测量基线特征、GHRT详情及GHRT的耐受性和长期安全性。

主要发现

  • 敏感性分析显示治疗期间女性IGF-1 SD评分持续低于正常更常见(P<0.001),男性高于正常更常见(P<0.001)。
  • 女性报告更多不良事件(P<0.001),尤其液体潴留相关症状,更常需减量或暂停GHRT(P=0.001)。
  • 按百分比计,两性停药率相同,发生2型糖尿病、良性肿瘤和肿瘤复发的风险也相同。
  • 男性发生恶性肿瘤的风险更高(P=0.012)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Previous studies report that outcomes of growth hormone (GH) replacement therapy (GHRT) might be less beneficial in growth hormone deficient (GHD) women compared with men. OBJECTIVE: This study investigated possible contributing factors regarding this previously found sex difference. METHODS: This retrospective cohort study, conducted at a nationwide outpatient clinic (the Dutch National Registry of GH Treatment in Adults), included Dutch adult GHD men (n = 1335) and women (n = 1251) treated with GHRT. The patients' baseline characteristics, details of GHRT, and the tolerability and long-term safety of GHRT were measured. RESULTS: During treatment, sensitivity analysis showed that insulin-like growth factor-1 (IGF-1) SD scores remained subnormal more often in women (P < 0.001), while scores above normal were more frequent in men (P < 0.001). Women reported more adverse events (P < 0.001), especially symptoms related to fluid retention, and more often needed a dose reduction or temporary stop of GHRT (P = 0.001). In percentages, both sexes equally discontinued GHRT, as was also true for the risk in developing type 2 diabetes mellitus, benign neoplasms, and tumor recurrence. The risk of developing malignant neoplasms was higher in men (P = 0.012). CONCLUSION: Data obtained from the Dutch National Registry of GH Treatment in Adults indicate that GHD women might be treated suboptimally, reflected as lower IGF-1 status and lower GHRT tolerability, leading to more frequent changes in treatment regimen but not discontinuation of GHRT. Regarding long-term safety, we found a higher risk for development of malignancies in GHD men.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Slagboom TNA, van Bunderen CC, van der Lely AJ, et al. Sex Differences in Long-Term Safety and Tolerability of GH Replacement Therapy in GH Deficient Adults. J Clin Endocrinol Metab. 2023. PMID: 36652411. doi:10.1210/clinem/dgad013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。